1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow IBI302: new trials by email Literature Review of IBI302 trials Research Report on IBI302
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD Aflibercept Ophthalmic, IBI302 - Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 600 | 2023-09-21 | 2025-03-13 |
Innovent Biologics (Suzhou) Co. Ltd. (1)
China (1)